There are four commonly mutated spliceosome proteins in hematological malignancies. In this interesting interview, recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), Omar Abdel-Wahab, MD from the Memorial Sloan Kettering Cancer Center, New York, NY, identifies these mutations, including the most common, which is in SRSF2. Dr Abdel-Wahab discusses how these mutations drive leukemogenesis.
The spliceosome mutations that can cause hematological malignancies
